NO317252B1 - 1-Substituerte-1-aminometyl-cykloalkanderivater (=gabapentinanaloger), deres fremstilling og deres anvendelse ved behandling av neurologiske lidelser - Google Patents
1-Substituerte-1-aminometyl-cykloalkanderivater (=gabapentinanaloger), deres fremstilling og deres anvendelse ved behandling av neurologiske lidelser Download PDFInfo
- Publication number
- NO317252B1 NO317252B1 NO20003039A NO20003039A NO317252B1 NO 317252 B1 NO317252 B1 NO 317252B1 NO 20003039 A NO20003039 A NO 20003039A NO 20003039 A NO20003039 A NO 20003039A NO 317252 B1 NO317252 B1 NO 317252B1
- Authority
- NO
- Norway
- Prior art keywords
- aminomethyl
- cyclopentyl
- methanesulfonamide
- dimethyl
- methyl
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 25
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical class OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title description 30
- 229960002870 gabapentin Drugs 0.000 title description 11
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims abstract description 23
- 230000036407 pain Effects 0.000 claims abstract description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 208000035475 disorder Diseases 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 9
- 230000036506 anxiety Effects 0.000 claims abstract description 9
- 206010015037 epilepsy Diseases 0.000 claims abstract description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 6
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 6
- 150000003456 sulfonamides Chemical group 0.000 claims abstract description 6
- 208000006083 Hypokinesia Diseases 0.000 claims abstract description 5
- 150000001408 amides Chemical group 0.000 claims abstract description 5
- 230000003483 hypokinetic effect Effects 0.000 claims abstract description 5
- 230000002981 neuropathic effect Effects 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 73
- 239000003814 drug Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- -1 1-aminomethyl-3-methyl-cyclohexyl Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 6
- MOEZPHHJIZLEKX-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclohexyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound N=1OC(=O)NC=1CC1(CN)CCCCC1 MOEZPHHJIZLEKX-UHFFFAOYSA-N 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- PPIQMYQQPKTQBZ-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cyclohexyl]ethyl]methanesulfonamide Chemical compound CS(=O)(=O)NCCC1(CN)CCCCC1 PPIQMYQQPKTQBZ-UHFFFAOYSA-N 0.000 claims description 3
- MIZFLIXVZLTPPF-NSHDSACASA-N 3-[[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1C(C)(C)CC[C@]1(CN)CC1=NOC(=O)N1 MIZFLIXVZLTPPF-NSHDSACASA-N 0.000 claims description 2
- MIZFLIXVZLTPPF-LLVKDONJSA-N 3-[[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1C(C)(C)CC[C@@]1(CN)CC1=NOC(=O)N1 MIZFLIXVZLTPPF-LLVKDONJSA-N 0.000 claims description 2
- FZIHJHCNFMHZNI-UHFFFAOYSA-N 3-[[1-(aminomethyl)cycloheptyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound N=1OC(=O)NC=1CC1(CN)CCCCCC1 FZIHJHCNFMHZNI-UHFFFAOYSA-N 0.000 claims description 2
- SQTCFPYBKMZTNR-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclopentyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound N=1OC(=O)NC=1CC1(CN)CCCC1 SQTCFPYBKMZTNR-UHFFFAOYSA-N 0.000 claims description 2
- CWSXPZYRFGYVBO-UHFFFAOYSA-N 4-methyl-2-(2h-tetrazol-5-ylmethyl)pentan-1-amine Chemical compound CC(C)CC(CN)CC1=NN=NN1 CWSXPZYRFGYVBO-UHFFFAOYSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- GSTZNOOCTKCLIZ-UHFFFAOYSA-N N-[2-(aminomethyl)-2-adamantyl]acetamide Chemical compound C(C)(=O)NC1(C2CC3CC(CC1C3)C2)CN GSTZNOOCTKCLIZ-UHFFFAOYSA-N 0.000 claims description 2
- XMOREOBNYOKDMM-SECBINFHSA-N [(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methanesulfonamide Chemical compound CC1(C)CC[C@@](CN)(CS(N)(=O)=O)C1 XMOREOBNYOKDMM-SECBINFHSA-N 0.000 claims description 2
- XMOREOBNYOKDMM-VIFPVBQESA-N [(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methanesulfonamide Chemical compound CC1(C)CC[C@](CN)(CS(N)(=O)=O)C1 XMOREOBNYOKDMM-VIFPVBQESA-N 0.000 claims description 2
- AULKEVUUBZJSRB-UHFFFAOYSA-N [1-(aminomethyl)-3,3-dimethylcyclobutyl]methanesulfonamide Chemical compound CC1(C)CC(CN)(CS(N)(=O)=O)C1 AULKEVUUBZJSRB-UHFFFAOYSA-N 0.000 claims description 2
- QLZZNFABZXIZCM-UHFFFAOYSA-N [1-(aminomethyl)cycloheptyl]methanesulfonamide Chemical compound NS(=O)(=O)CC1(CN)CCCCCC1 QLZZNFABZXIZCM-UHFFFAOYSA-N 0.000 claims description 2
- SRFGZWYLQJNPEF-UHFFFAOYSA-N [1-(aminomethyl)cyclohexyl]methanesulfonic acid Chemical compound OS(=O)(=O)CC1(CN)CCCCC1 SRFGZWYLQJNPEF-UHFFFAOYSA-N 0.000 claims description 2
- XMTHBBOVDHYRHW-UHFFFAOYSA-N [1-(aminomethyl)cyclopentyl]methanesulfonamide Chemical compound NS(=O)(=O)CC1(CN)CCCC1 XMTHBBOVDHYRHW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- AHDLFZFBRTXUOE-NSHDSACASA-N n-[2-[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]ethyl]methanesulfonamide Chemical compound CC1(C)CC[C@](CN)(CCNS(C)(=O)=O)C1 AHDLFZFBRTXUOE-NSHDSACASA-N 0.000 claims description 2
- AHDLFZFBRTXUOE-LLVKDONJSA-N n-[2-[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]ethyl]methanesulfonamide Chemical compound CC1(C)CC[C@@](CN)(CCNS(C)(=O)=O)C1 AHDLFZFBRTXUOE-LLVKDONJSA-N 0.000 claims description 2
- MZLHDSAVPXLKBD-NXEZZACHSA-N n-[2-[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]ethyl]methanesulfonamide Chemical compound C[C@@H]1CC(CN)(CCNS(C)(=O)=O)C[C@H]1C MZLHDSAVPXLKBD-NXEZZACHSA-N 0.000 claims description 2
- JBWVVELZPWDWFW-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cycloheptyl]ethyl]methanesulfonamide Chemical compound CS(=O)(=O)NCCC1(CN)CCCCCC1 JBWVVELZPWDWFW-UHFFFAOYSA-N 0.000 claims description 2
- KBPINOMTMTWDSK-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cyclopentyl]ethyl]methanesulfonamide Chemical compound CS(=O)(=O)NCCC1(CN)CCCC1 KBPINOMTMTWDSK-UHFFFAOYSA-N 0.000 claims description 2
- 208000003443 Unconsciousness Diseases 0.000 claims 1
- AXPYNQKQGUJNSB-JTQLQIEISA-N [(1r)-3,3-dimethyl-1-(2h-tetrazol-5-ylmethyl)cyclopentyl]methanamine Chemical compound C1C(C)(C)CC[C@]1(CN)CC1=NN=NN1 AXPYNQKQGUJNSB-JTQLQIEISA-N 0.000 claims 1
- VWMFPMMAWJKGGU-HTQZYQBOSA-N [(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]methanesulfonamide Chemical compound C[C@@H]1CC(CN)(CS(N)(=O)=O)C[C@H]1C VWMFPMMAWJKGGU-HTQZYQBOSA-N 0.000 claims 1
- YNVVZQUWWLOVIB-HTQZYQBOSA-N [(3r,4r)-3,4-dimethyl-1-(2h-tetrazol-5-ylmethyl)cyclopentyl]methanamine Chemical compound C1[C@@H](C)[C@H](C)CC1(CN)CC1=NN=NN1 YNVVZQUWWLOVIB-HTQZYQBOSA-N 0.000 claims 1
- GTSLDHDWPQDRMR-UHFFFAOYSA-N [1-(aminomethyl)cyclohexyl]methanesulfonamide Chemical compound NS(=O)(=O)CC1(CN)CCCCC1 GTSLDHDWPQDRMR-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical group C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 79
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 29
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 14
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 9
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- OFUQZEVBAUYZJB-HTQZYQBOSA-N (3r,4r)-3,4-dimethyl-1-(2h-tetrazol-5-ylmethyl)cyclopentane-1-carbonitrile Chemical compound C1[C@@H](C)[C@H](C)CC1(C#N)CC1=NN=NN1 OFUQZEVBAUYZJB-HTQZYQBOSA-N 0.000 description 8
- NBJOLXRICAAKTE-UHFFFAOYSA-N 2-[1-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]cyclohexyl]acetic acid;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)NCC1(CC(O)=O)CCCCC1 NBJOLXRICAAKTE-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229960001171 acetohydroxamic acid Drugs 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- GXLDCDIGAKAJSB-UHFFFAOYSA-N tert-butyl n-[[1-(2-amino-2-oxoethyl)cyclohexyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1(CC(N)=O)CCCCC1 GXLDCDIGAKAJSB-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 7
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ORDRYYZMZDILKB-SCLLHFNJSA-N [(3r,4r)-3,4-dimethyl-1-(2h-tetrazol-5-ylmethyl)cyclopentyl]methanamine;hydrochloride Chemical compound Cl.C1[C@@H](C)[C@H](C)CC1(CN)CC1=NN=NN1 ORDRYYZMZDILKB-SCLLHFNJSA-N 0.000 description 6
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 230000000112 colonic effect Effects 0.000 description 5
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000036651 mood Effects 0.000 description 5
- HOFBIVOLROWHNN-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cyclohexyl]ethyl]methanesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)NCCC1(CN)CCCCC1 HOFBIVOLROWHNN-UHFFFAOYSA-N 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 230000003040 nociceptive effect Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 241001515942 marmosets Species 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 150000003536 tetrazoles Chemical class 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- YAZHHBCPHZIIFT-UHFFFAOYSA-N 2-[1-(nitromethyl)cyclohexyl]acetonitrile Chemical compound [O-][N+](=O)CC1(CC#N)CCCCC1 YAZHHBCPHZIIFT-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 229940072228 neurontin Drugs 0.000 description 3
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- RSADXHRBAHWEBU-UHFFFAOYSA-N tert-butyl n-[[1-[(5-sulfanylidene-2h-1,2,4-oxadiazol-3-yl)methyl]cyclohexyl]methyl]carbamate Chemical compound N=1OC(=S)NC=1CC1(CNC(=O)OC(C)(C)C)CCCCC1 RSADXHRBAHWEBU-UHFFFAOYSA-N 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000009935 visceral pain Diseases 0.000 description 3
- AVHPQYDZTCVXRF-UHFFFAOYSA-N 2-[1-(nitromethyl)cyclohexyl]ethanamine Chemical compound NCCC1(C[N+]([O-])=O)CCCCC1 AVHPQYDZTCVXRF-UHFFFAOYSA-N 0.000 description 2
- YOOHANJKYCQHED-UHFFFAOYSA-N 2-[1-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]cyclohexyl]acetic acid Chemical compound CC(C)(C)OC(=O)NCC1(CC(O)=O)CCCCC1 YOOHANJKYCQHED-UHFFFAOYSA-N 0.000 description 2
- VLRQRRQHXZCEDL-UHFFFAOYSA-N 2-cyclohexylideneacetonitrile Chemical compound N#CC=C1CCCCC1 VLRQRRQHXZCEDL-UHFFFAOYSA-N 0.000 description 2
- WKRGKOJFYZDTNM-UHFFFAOYSA-N 9-(2h-tetrazol-5-ylmethyl)bicyclo[3.3.1]nonane-9-carbonitrile Chemical compound C1CCC2CCCC1C2(C#N)CC1=NN=NN1 WKRGKOJFYZDTNM-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001107 psychogenic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- AHSMEIUFEMQLAD-UHFFFAOYSA-N tert-butyl n-[[1-(cyanomethyl)cyclohexyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1(CC#N)CCCCC1 AHSMEIUFEMQLAD-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LITYSRRJCUQLBN-RKDXNWHRSA-N (3r,4r)-1-(cyanomethyl)-3,4-dimethylcyclopentane-1-carbonitrile Chemical compound C[C@@H]1CC(CC#N)(C#N)C[C@H]1C LITYSRRJCUQLBN-RKDXNWHRSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CDTLIAYFTKCTFV-UHFFFAOYSA-N 1-(2h-tetrazol-5-ylmethyl)cyclohexane-1-carbonitrile Chemical compound N=1N=NNC=1CC1(C#N)CCCCC1 CDTLIAYFTKCTFV-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- DTJLDOBNCXMANO-UHFFFAOYSA-N 2-(2h-tetrazol-5-ylmethyl)adamantane-2-carbonitrile Chemical compound C1C2CC(C3)CC1CC3C2(C#N)CC1=NN=NN1 DTJLDOBNCXMANO-UHFFFAOYSA-N 0.000 description 1
- ZONTWIUNHYLDLZ-JTQLQIEISA-N 2-[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]-n-hydroxyacetamide Chemical compound CC1(C)CC[C@](CN)(CC(=O)NO)C1 ZONTWIUNHYLDLZ-JTQLQIEISA-N 0.000 description 1
- ZONTWIUNHYLDLZ-SNVBAGLBSA-N 2-[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]-n-hydroxyacetamide Chemical compound CC1(C)CC[C@@](CN)(CC(=O)NO)C1 ZONTWIUNHYLDLZ-SNVBAGLBSA-N 0.000 description 1
- BQOLBIIAWFGWEW-HTQZYQBOSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]-n-hydroxyacetamide Chemical compound C[C@@H]1CC(CN)(CC(=O)NO)C[C@H]1C BQOLBIIAWFGWEW-HTQZYQBOSA-N 0.000 description 1
- RVJMNFWHJKSARF-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dimethylcyclobutyl]-n-hydroxyacetamide Chemical compound CC1(C)CC(CN)(CC(=O)NO)C1 RVJMNFWHJKSARF-UHFFFAOYSA-N 0.000 description 1
- SDJDLWRYIIIDMH-UHFFFAOYSA-N 2-[1-(aminomethyl)cycloheptyl]-n-hydroxyacetamide Chemical compound ONC(=O)CC1(CN)CCCCCC1 SDJDLWRYIIIDMH-UHFFFAOYSA-N 0.000 description 1
- HKBYROVPIYTBLO-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclohexyl]-n-hydroxyacetamide Chemical compound ONC(=O)CC1(CN)CCCCC1 HKBYROVPIYTBLO-UHFFFAOYSA-N 0.000 description 1
- GQLYDXGALKBIST-UHFFFAOYSA-N 2-[2-(aminomethyl)-2-adamantyl]-n-hydroxyacetamide Chemical compound C1C(C2)CC3CC1C(CN)(CC(=O)NO)C2C3 GQLYDXGALKBIST-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- ZMGMYCHEWPVBEL-UHFFFAOYSA-N 3,4-dimethylcyclopentan-1-one Chemical compound CC1CC(=O)CC1C ZMGMYCHEWPVBEL-UHFFFAOYSA-N 0.000 description 1
- AIWARZDEPWJRDC-NSHDSACASA-N 3-[[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1C(C)(C)CC[C@]1(CN)CC1=NOC(=S)N1 AIWARZDEPWJRDC-NSHDSACASA-N 0.000 description 1
- LDNRKBMOYVWRKL-HTQZYQBOSA-N 3-[[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1[C@@H](C)[C@H](C)CC1(CN)CC1=NOC(=O)N1 LDNRKBMOYVWRKL-HTQZYQBOSA-N 0.000 description 1
- QSQKTUOPGLSZNK-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3,3-dimethylcyclobutyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1C(C)(C)CC1(CN)CC1=NOC(=O)N1 QSQKTUOPGLSZNK-UHFFFAOYSA-N 0.000 description 1
- FGLLHIYNJXAYPA-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3,3-dimethylcyclobutyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1C(C)(C)CC1(CN)CC1=NOC(=S)N1 FGLLHIYNJXAYPA-UHFFFAOYSA-N 0.000 description 1
- CYKDJZAVCLPOQA-UHFFFAOYSA-N 3-[[1-(aminomethyl)cycloheptyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound N=1OC(=S)NC=1CC1(CN)CCCCCC1 CYKDJZAVCLPOQA-UHFFFAOYSA-N 0.000 description 1
- NISSXCGKGSMLOH-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclohexyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound N=1OC(=S)NC=1CC1(CN)CCCCC1 NISSXCGKGSMLOH-UHFFFAOYSA-N 0.000 description 1
- PYPDLBWATDGFFS-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclopentyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound N=1OC(=S)NC=1CC1(CN)CCCC1 PYPDLBWATDGFFS-UHFFFAOYSA-N 0.000 description 1
- VXFRREOVJUORQT-UHFFFAOYSA-N 3-[[2-(aminomethyl)-2-adamantyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1C2CC(C3)CC1CC3C2(CN)CC1=NOC(=O)N1 VXFRREOVJUORQT-UHFFFAOYSA-N 0.000 description 1
- HXBVPQVJCKCUDB-UHFFFAOYSA-N 3-[[2-(aminomethyl)-2-adamantyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1C2CC(C3)CC1CC3C2(CN)CC1=NOC(=S)N1 HXBVPQVJCKCUDB-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000024255 Audiogenic seizures Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000288950 Callithrix jacchus Species 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- CHNUNORXWHYHNE-UHFFFAOYSA-N Oxadiazon Chemical compound C1=C(Cl)C(OC(C)C)=CC(N2C(OC(=N2)C(C)(C)C)=O)=C1Cl CHNUNORXWHYHNE-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- AXPYNQKQGUJNSB-SNVBAGLBSA-N [(1s)-3,3-dimethyl-1-(2h-tetrazol-5-ylmethyl)cyclopentyl]methanamine Chemical compound C1C(C)(C)CC[C@@]1(CN)CC1=NN=NN1 AXPYNQKQGUJNSB-SNVBAGLBSA-N 0.000 description 1
- SJWIXWLQZNLVNK-UHFFFAOYSA-N [9-(aminomethyl)-9-bicyclo[3.3.1]nonanyl]methanesulfonamide Chemical compound C1CCC2CCCC1C2(CS(N)(=O)=O)CN SJWIXWLQZNLVNK-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003574 anti-allodynic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002585 cerebral angiography Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- VLVOEGVIDIDILV-RKDXNWHRSA-N ethyl 2-cyano-2-[(3r,4r)-3,4-dimethylcyclopentylidene]acetate Chemical compound CCOC(=O)C(C#N)=C1C[C@@H](C)[C@H](C)C1 VLVOEGVIDIDILV-RKDXNWHRSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- LSFFIHRMUCYKDJ-UHFFFAOYSA-N n-(2-methoxyethyl)-n'-(2,2,6,6-tetramethylpiperidin-4-yl)oxamide Chemical compound COCCNC(=O)C(=O)NC1CC(C)(C)NC(C)(C)C1 LSFFIHRMUCYKDJ-UHFFFAOYSA-N 0.000 description 1
- LROIESVTNILZEA-JTQLQIEISA-N n-[2-[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC1(C)CC[C@](CN)(CCNS(=O)(=O)C(F)(F)F)C1 LROIESVTNILZEA-JTQLQIEISA-N 0.000 description 1
- VCCMBMLHCPHYBL-RKDXNWHRSA-N n-[2-[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound C[C@@H]1CC(CN)(CCNS(=O)(=O)C(F)(F)F)C[C@H]1C VCCMBMLHCPHYBL-RKDXNWHRSA-N 0.000 description 1
- YYJIVWAHSQHIKF-UHFFFAOYSA-N n-[2-[1-(aminomethyl)-3,3-dimethylcyclobutyl]ethyl]methanesulfonamide Chemical compound CC1(C)CC(CN)(CCNS(C)(=O)=O)C1 YYJIVWAHSQHIKF-UHFFFAOYSA-N 0.000 description 1
- MSNUDYNNVPVGSB-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cycloheptyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NCCC1(CN)CCCCCC1 MSNUDYNNVPVGSB-UHFFFAOYSA-N 0.000 description 1
- QDOYJOITJAVZIU-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cyclohexyl]ethyl]acetamide;hydrochloride Chemical compound Cl.CC(=O)NCCC1(CN)CCCCC1 QDOYJOITJAVZIU-UHFFFAOYSA-N 0.000 description 1
- LIXJGZRNWIQRJA-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cyclopentyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NCCC1(CN)CCCC1 LIXJGZRNWIQRJA-UHFFFAOYSA-N 0.000 description 1
- MOFZATJKQIJHRP-UHFFFAOYSA-N n-[2-[1-(nitromethyl)cyclohexyl]ethyl]acetamide Chemical compound CC(=O)NCCC1(C[N+]([O-])=O)CCCCC1 MOFZATJKQIJHRP-UHFFFAOYSA-N 0.000 description 1
- VZDKAUAVCZUTQF-UHFFFAOYSA-N n-[2-[2-(aminomethyl)-2-adamantyl]ethyl]methanesulfonamide Chemical compound C1C(C2)CC3CC1C(CCNS(=O)(=O)C)(CN)C2C3 VZDKAUAVCZUTQF-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000030062 persistent idiopathic facial pain Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical class [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000003093 somatogenic effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/14—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/33—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/383—Cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/46—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing nine carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6977397P | 1997-12-16 | 1997-12-16 | |
US10500598P | 1998-10-20 | 1998-10-20 | |
PCT/US1998/023918 WO1999031075A1 (en) | 1997-12-16 | 1998-11-10 | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20003039D0 NO20003039D0 (no) | 2000-06-14 |
NO20003039L NO20003039L (no) | 2000-06-14 |
NO317252B1 true NO317252B1 (no) | 2004-09-27 |
Family
ID=26750409
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20003039A NO317252B1 (no) | 1997-12-16 | 2000-06-14 | 1-Substituerte-1-aminometyl-cykloalkanderivater (=gabapentinanaloger), deres fremstilling og deres anvendelse ved behandling av neurologiske lidelser |
NO20041112A NO20041112L (no) | 1997-12-16 | 2004-03-17 | 1-Substituerte-1-aminometyl-cykloalkanderivater (=gabapentinanaloger), deres fremstilling og deres anvendelse ved behandiing av neurologiske lidelser |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20041112A NO20041112L (no) | 1997-12-16 | 2004-03-17 | 1-Substituerte-1-aminometyl-cykloalkanderivater (=gabapentinanaloger), deres fremstilling og deres anvendelse ved behandiing av neurologiske lidelser |
Country Status (22)
Country | Link |
---|---|
US (1) | US6518289B1 (de) |
EP (2) | EP1047678B1 (de) |
JP (1) | JP2002508362A (de) |
KR (1) | KR20010033158A (de) |
CN (2) | CN1495160A (de) |
AT (1) | ATE275552T1 (de) |
AU (1) | AU765802B2 (de) |
BR (1) | BR9814286A (de) |
CA (1) | CA2304974C (de) |
DE (1) | DE69826151T2 (de) |
ES (1) | ES2227896T3 (de) |
HK (1) | HK1032966A1 (de) |
HU (1) | HUP0004439A3 (de) |
IL (1) | IL135313A0 (de) |
IS (1) | IS5435A (de) |
NO (2) | NO317252B1 (de) |
NZ (1) | NZ503963A (de) |
PL (1) | PL341291A1 (de) |
PT (1) | PT1047678E (de) |
SI (1) | SI1047678T1 (de) |
TR (1) | TR200001795T2 (de) |
WO (1) | WO1999031075A1 (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010033153A (ko) * | 1997-12-16 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 4(3)-치환-4(3)-아미노메틸-(티오)피란 또는 -피페리딘유도체(=가바펜틴 동족체), 그의 제법 및 신경 질환 치료용도 |
GB9901691D0 (en) | 1999-01-26 | 1999-03-17 | Cerebrus Ltd | Chemical compounds |
TWI238062B (en) * | 1999-12-01 | 2005-08-21 | Ucb Sa | A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders |
GB2362646A (en) * | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
EP1343805A4 (de) | 2000-10-06 | 2005-07-20 | Xenoport Inc | Von gallensäuren abgeleitete verbindungen für die bereitstellung anhaltender systemischer konzentrationen von arzneimitteln nach oraler verabreichung |
EP1361847A2 (de) | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Gallensäurekonjugate zur bereitstellung anhaltender systemischer arneimittelkonzentrationen |
US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
PL366406A1 (en) | 2001-04-19 | 2005-01-24 | Warner-Lambert Company Llc | Fused bicyclic or tricyclic amino acids |
ES2296956T5 (es) | 2001-06-11 | 2011-07-12 | Xenoport, Inc. | Profármacos de análogos de gaba, composiciones y sus usos. |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1412324A4 (de) | 2001-06-11 | 2004-09-29 | Xenoport Inc | Aminosäurekonjugate, die anhaltende systemische konzentrationen von gaba-analoga ergeben |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
JP2005521664A (ja) | 2002-01-31 | 2005-07-21 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 耳鳴を治療するためのアルファ2デルタ・リガンド |
AU2002316231A1 (en) | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
WO2003080588A1 (en) | 2002-03-20 | 2003-10-02 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
WO2003099338A2 (en) | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
WO2004002462A2 (en) * | 2002-06-27 | 2004-01-08 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
US7060727B2 (en) | 2002-12-11 | 2006-06-13 | Xenoport, Inc. | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof |
DE60332387D1 (de) | 2002-12-13 | 2010-06-10 | Warner Lambert Co | Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
BRPI0408110A (pt) | 2003-03-07 | 2006-03-01 | Warner Lambert Co | derivados de beta-aminoácido substituìdos com tetrazol e oxadiazolona |
WO2005013888A2 (en) * | 2003-05-14 | 2005-02-17 | Cytokinetics, Inc. | Compounds, compositions and methods |
WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
KR20060119971A (ko) | 2003-09-11 | 2006-11-24 | 제노포트 인코포레이티드 | Gaba 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방 |
CN1849153A (zh) | 2003-09-12 | 2006-10-18 | 辉瑞大药厂 | 含有α-2-δ配体和5-羟色胺/去甲肾上腺素重摄取抑制剂的组合物 |
CN1871021B (zh) | 2003-09-17 | 2010-07-28 | 什诺波特有限公司 | 用gaba类似物的前药治疗或预防多动腿综合征 |
SI1677767T1 (sl) | 2003-10-14 | 2011-11-30 | Xenoport Inc | Kristalinična oblika analoga gama-aminomaslene kisline |
DK1691811T3 (da) | 2003-12-11 | 2014-10-20 | Sunovion Pharmaceuticals Inc | Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression |
US20050209319A1 (en) * | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
BRPI0517227B8 (pt) | 2004-11-04 | 2021-05-25 | Xenoport Inc | comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido |
EP1820502A1 (de) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Wirkstoffzusammensetzungen enthaltend Azolycarbinolderivate |
BRPI0709961A2 (pt) * | 2006-04-11 | 2011-08-02 | Novartis Ag | compostos orgánicos |
AR061728A1 (es) * | 2006-06-30 | 2008-09-17 | Pfizer Prod Inc | Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1 |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8278355B2 (en) | 2006-09-12 | 2012-10-02 | Therexcell Pharma Inc. | Isovaline for treatment of pain |
RS51940B (en) | 2006-12-22 | 2012-02-29 | Recordati Ireland Limited | Combined TH2δ LIGANAD THERAPY AND NSAID FOR LOWER URINARY TRACT DISORDERS |
US20130012485A1 (en) * | 2006-12-22 | 2013-01-10 | Baeschlin Daniel Kaspar | Organic compounds |
WO2008155619A2 (en) * | 2007-06-21 | 2008-12-24 | Pfizer Inc. | Preparation of optically-active cyclic amino acids |
CN102316888A (zh) * | 2007-08-23 | 2012-01-11 | 利兰斯坦福青年大学托管委员会 | 突触发生的调控 |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7872046B2 (en) | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
TWI369202B (en) | 2008-01-25 | 2012-08-01 | Xenoport Inc | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
WO2009105887A1 (en) * | 2008-02-26 | 2009-09-03 | Ernest Puil | Cyclic amino acids for the treatment of pain |
EP2116539A1 (de) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon |
CN102216257B (zh) | 2008-10-08 | 2015-11-25 | 凯飞药业公司 | Gaba偶联物及其使用方法 |
EP2353598A1 (de) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz |
EP2353591A1 (de) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon |
EP2388005A1 (de) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie |
EP2415471A1 (de) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie |
EP2524694A1 (de) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes |
US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
HUE047629T2 (hu) | 2013-01-28 | 2020-05-28 | Lopez Hector L | Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása |
TN2016000228A1 (en) | 2013-12-17 | 2017-10-06 | Esteve Labor Dr | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS. |
TN2016000229A1 (en) | 2013-12-17 | 2017-10-06 | Esteve Labor Dr | Gabapentinoids and sigma receptor ligands combinations. |
AU2014364693B2 (en) * | 2013-12-18 | 2018-12-06 | Novassay Sa | Gamma-aminobutyric acid (GABA) analogues for the treatment of pain and other disorders |
SG11201606351VA (en) | 2014-02-03 | 2016-09-29 | Quadriga Biosciences Inc | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
BR112016017993A2 (pt) | 2014-02-03 | 2017-08-08 | Quadriga Biosciences Inc | Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos |
WO2017024009A1 (en) | 2015-08-03 | 2017-02-09 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
EP4227293A3 (de) | 2018-05-14 | 2023-10-04 | Xgene Pharmaceutical Inc | Kristalline formen von 1-(acyloxy)-alkylcarbamat-wirkstoffkonjugaten von naproxen und pregabalin |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6804065A (de) * | 1968-03-22 | 1969-09-24 | ||
BE789025A (fr) * | 1971-09-23 | 1973-03-20 | Allen & Hanburys Ltd | Nouvelles ethylene diamines substituees |
US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE2962724D1 (en) * | 1978-10-13 | 1982-06-24 | Janssen Pharmaceutica Nv | Novel (1-substituted) cycloalkylmethyl-isothiocyanates, a process for their preparation, compositions comprising them, and their use as pesticides |
DE3300774A1 (de) * | 1983-01-12 | 1984-07-12 | Hoechst Ag, 6230 Frankfurt | Neue spirocyclische aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue spirocyclische aminosaeuren als zwischenprodukte und verfahren zu deren herstellung |
DE3327318C1 (de) * | 1983-07-29 | 1985-03-14 | Gödecke AG, 1000 Berlin | 1-Aminomethylcyclohexylmethan-sulfonsaeure,Verfahren zu deren Herstellung und deren Verwendung |
US4755594A (en) * | 1986-01-31 | 1988-07-05 | Warner-Lambert Company | N6 -substituted adenosines |
DE3634066A1 (de) * | 1986-10-07 | 1988-04-21 | Boehringer Mannheim Gmbh | Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel |
US5015644A (en) * | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
FR2674522B1 (fr) * | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
FR2687402B1 (fr) * | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
CA2123728A1 (en) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
JPH07101929A (ja) * | 1993-10-01 | 1995-04-18 | Fujisawa Pharmaceut Co Ltd | 尿素誘導体およびその製造法 |
NZ331142A (en) * | 1996-03-14 | 2001-04-27 | Warner Lambert Co | Bridged cyclic amino acids as pharmaceutical agents |
EP0888286B1 (de) * | 1996-03-14 | 2001-10-31 | Warner-Lambert Company | Zyklische aminosäure als pharmazeutische wirkstoffe |
NZ333038A (en) * | 1996-08-22 | 2000-10-27 | Warner Lambert Co | Non-peptide bombesin receptor antagonists |
-
1998
- 1998-11-10 CN CNA2003101142270A patent/CN1495160A/zh active Pending
- 1998-11-10 IL IL13531398A patent/IL135313A0/xx unknown
- 1998-11-10 CA CA002304974A patent/CA2304974C/en not_active Expired - Fee Related
- 1998-11-10 BR BR9814286-0A patent/BR9814286A/pt not_active Application Discontinuation
- 1998-11-10 CN CN98811481XA patent/CN1131855C/zh not_active Expired - Fee Related
- 1998-11-10 AT AT98957745T patent/ATE275552T1/de not_active IP Right Cessation
- 1998-11-10 TR TR2000/01795T patent/TR200001795T2/xx unknown
- 1998-11-10 PL PL98341291A patent/PL341291A1/xx unknown
- 1998-11-10 EP EP98957745A patent/EP1047678B1/de not_active Expired - Lifetime
- 1998-11-10 ES ES98957745T patent/ES2227896T3/es not_active Expired - Lifetime
- 1998-11-10 NZ NZ503963A patent/NZ503963A/xx unknown
- 1998-11-10 WO PCT/US1998/023918 patent/WO1999031075A1/en not_active Application Discontinuation
- 1998-11-10 JP JP2000539002A patent/JP2002508362A/ja active Pending
- 1998-11-10 DE DE69826151T patent/DE69826151T2/de not_active Expired - Fee Related
- 1998-11-10 SI SI9830690T patent/SI1047678T1/xx unknown
- 1998-11-10 US US09/509,905 patent/US6518289B1/en not_active Expired - Fee Related
- 1998-11-10 EP EP04006036A patent/EP1475371A1/de not_active Withdrawn
- 1998-11-10 AU AU13929/99A patent/AU765802B2/en not_active Ceased
- 1998-11-10 HU HU0004439A patent/HUP0004439A3/hu unknown
- 1998-11-10 PT PT98957745T patent/PT1047678E/pt unknown
- 1998-11-10 KR KR1020007006535A patent/KR20010033158A/ko not_active Application Discontinuation
-
2000
- 2000-04-07 IS IS5435A patent/IS5435A/is unknown
- 2000-06-14 NO NO20003039A patent/NO317252B1/no not_active IP Right Cessation
-
2001
- 2001-05-23 HK HK01103570A patent/HK1032966A1/xx not_active IP Right Cessation
-
2004
- 2004-03-17 NO NO20041112A patent/NO20041112L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL135313A0 (en) | 2001-05-20 |
NO20041112L (no) | 2000-06-14 |
PT1047678E (pt) | 2004-12-31 |
ES2227896T3 (es) | 2005-04-01 |
BR9814286A (pt) | 2000-10-03 |
JP2002508362A (ja) | 2002-03-19 |
HUP0004439A3 (en) | 2001-12-28 |
ATE275552T1 (de) | 2004-09-15 |
EP1047678A1 (de) | 2000-11-02 |
EP1475371A1 (de) | 2004-11-10 |
SI1047678T1 (en) | 2005-02-28 |
CN1131855C (zh) | 2003-12-24 |
IS5435A (is) | 2000-04-07 |
NO20003039D0 (no) | 2000-06-14 |
HUP0004439A2 (hu) | 2001-10-28 |
US6518289B1 (en) | 2003-02-11 |
NO20003039L (no) | 2000-06-14 |
WO1999031075A1 (en) | 1999-06-24 |
CA2304974C (en) | 2005-10-25 |
AU765802B2 (en) | 2003-10-02 |
NZ503963A (en) | 2002-09-27 |
CN1495160A (zh) | 2004-05-12 |
PL341291A1 (en) | 2001-04-09 |
EP1047678B1 (de) | 2004-09-08 |
AU1392999A (en) | 1999-07-05 |
CN1279674A (zh) | 2001-01-10 |
CA2304974A1 (en) | 1999-06-24 |
HK1032966A1 (en) | 2001-08-10 |
DE69826151T2 (de) | 2005-01-27 |
TR200001795T2 (tr) | 2000-11-21 |
DE69826151D1 (de) | 2004-10-14 |
KR20010033158A (ko) | 2001-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO317252B1 (no) | 1-Substituerte-1-aminometyl-cykloalkanderivater (=gabapentinanaloger), deres fremstilling og deres anvendelse ved behandling av neurologiske lidelser | |
EP1045839B1 (de) | ((cyclo)alkyl substituierte)-.gamma.-aminobuttersäure derivate (=gaba analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen | |
CA2304967C (en) | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders | |
EP0888325B1 (de) | Zyklischaminosäure als pharmazeutische mittel | |
AU731279B2 (en) | Novel bridged cyclic amino acids as pharmaceutical agents | |
CZ286398A3 (cs) | Nové substituované cyklické aminokyseliny jako farmaceutická činidla | |
EP1187832B1 (de) | Amino-heterocyclen zur verwendung als pharmazeutische mittel | |
CA2245647C (en) | Novel bridged cyclic amino acids as pharmaceutical agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |